Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ranpirnase - Orgenesis

Drug Profile

Ranpirnase - Orgenesis

Alternative Names: Amphibian ribonuclease A; Onconase; P-30 protein - Alfacell; P-30 ribonuclease

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alfacell Corporation
  • Developer Alfacell Corporation; Orgenesis; Tamir Biotechnology
  • Class Antineoplastics; Antivirals; Eye disorder therapies; Ribonucleases
  • Mechanism of Action Apoptosis stimulants; Protein synthesis inhibitors; Ribonuclease replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma; Ebola virus infections
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Genital warts
  • No development reported COVID 2019 infections; Ebola virus infections; HIV infections; Zika virus infection
  • Discontinued Acute myeloid leukaemia; Brain cancer; Chronic lymphocytic leukaemia; Mesothelioma; Neuroblastoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in USA (Parenteral)
  • 28 Apr 2022 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA (Parenteral)
  • 28 Apr 2022 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top